Zobrazeno 1 - 10
of 17
pro vyhledávání: ''
Publikováno v:
JAMA: The Journal of the American Medical Association. 267:2328
To the Editor. —The significance of lipoprotein(a) [Lp(a)] as a genetic risk factor for atherosclerotic vascular disease has been well documented.1-3However, many aspects of its metabolism remain unclear.1,2There have been reports that Lp(a) is rem
Autor:
Terry A. Jacobson, Kevin A. Shulman, Henry A. Glick, Mary Kaye Willian, Harris Koffer, John M. Eisenberg, Bruce Kinosian
Publikováno v:
JAMA: The Journal of the American Medical Association. 265:1950
In Reply. — Drs Bentkover, Boselli, and Lambird raise several issues concerning our article; the principal ones concern our construction of the LDL-HDL index, our analytic perspective, and the costs of side effects. We address these in turn. Dr Ben
Lovastatin Efficacy in Reducing Low-Density Lipoprotein Cholesterol Levels on High- vs Low-Fat Diets
Publikováno v:
JAMA: The Journal of the American Medical Association. 265:997
The effectiveness of lovastatin was compared with both a high-fat vs low-fat diet. Hypercholesterolemic subjects were studied under metabolic ward conditions for diet periods of 3 weeks while receiving lovastatin (40 mg/d) or placebo. Multiple lipopr
Publikováno v:
JAMA: The Journal of the American Medical Association. 222:676-681
Two bile acid-sequestrant anion exchange resins, colestipol (U-26, 597A) and cholestyramine resin (Questran), were given in doses of 20 gm/day for four months each in a 14-month placebo crossover study to 25 patients with familial type II hyperlipopr
Autor:
Jonathan A. Tobert
Publikováno v:
JAMA: The Journal of the American Medical Association. 260:3591
In Reply. — In response to Dr Goldstein, our study was a comparison of the tolerability and lipid-lowering effects of lovastatin and cholestyramine, so that our conclusion that lovastatin is more effective than cholestyramine applies only to the ef
Autor:
Eileen M. Cullinane, Claire Chenevert, Stanley P. Sady, Peter N. Herbert, Paul D. Thompson, Mina A. Sady, Ann Saritelli
Publikováno v:
JAMA: The Journal of the American Medical Association. 261:1165
Oral anabolic steroids produce striking reductions in serum concentrations of high-density lipoprotein (HDL) cholesterol. We hypothesized that this effect related to their route of administration and was unrelated to their androgenic potency. We admi
Publikováno v:
JAMA: The Journal of the American Medical Association. 256:2843
Patients with homozygous familial hypercholesterolemia produce no normal low-density lipoprotein (LDL) receptors, and as a result, LDL accumulates in plasma, causing severe premature atherosclerosis. Two years ago, liver transplantation was performed
Publikováno v:
JAMA: The Journal of the American Medical Association. 261:2332
In Reply.— We appreciate the comments of Dr Goldstein and Drs Mazur and Herbert regarding our recent report in JAMA . We have data available on changes in low-density lipoprotein and high-density lipoprotein (HDL) cholesterol concentrations in five
Autor:
Beverly Merz
Publikováno v:
JAMA: The Journal of the American Medical Association. 257:2135
WHILE CLINICAL investigators continue their empirical search for the optimum aspirin dose to prevent thrombogenesis, basic researchers have been looking at the effect of aspirin on two prostaglandins that are instrumental in clot formation. Laborator
Autor:
Scott M. Grundy, Gloria Lena Vega
Publikováno v:
JAMA: The Journal of the American Medical Association. 262:3148
This study compared lovastatin and gemfibrozil therapy for effects on lipid and lipoprotein levels in 22 normolipidemic patients with reduced high-density lipoprotein cholesterol levels. Most patients had coronary heart disease. A randomized, crossov